Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068739/
https://www.ncbi.nlm.nih.gov/pubmed/32201507
http://dx.doi.org/10.1177/1758835920913426
_version_ 1783505643795120128
collection PubMed
description
format Online
Article
Text
id pubmed-7068739
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-70687392020-03-20 Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma Ther Adv Med Oncol Erratum SAGE Publications 2020-03-12 /pmc/articles/PMC7068739/ /pubmed/32201507 http://dx.doi.org/10.1177/1758835920913426 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Erratum
Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
title Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
title_full Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
title_fullStr Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
title_full_unstemmed Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
title_short Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
title_sort erratum to a phase ii study of the efficacy and safety of the met inhibitor capmatinib (inc280) in patients with advanced hepatocellular carcinoma
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068739/
https://www.ncbi.nlm.nih.gov/pubmed/32201507
http://dx.doi.org/10.1177/1758835920913426

Ejemplares similares